Aspire Capital Advisors LLC Buys New Shares in Bristol Myers Squibb Company $BMY

Aspire Capital Advisors LLC purchased a new position in Bristol Myers Squibb Company (NYSE:BMY) in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 11,209 shares of the biopharmaceutical company’s stock, valued at approximately $506,000.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. IMA Advisory Services Inc. boosted its position in shares of Bristol Myers Squibb by 22.7% in the third quarter. IMA Advisory Services Inc. now owns 1,890 shares of the biopharmaceutical company’s stock worth $85,000 after purchasing an additional 350 shares during the period. Abich Financial Wealth Management LLC bought a new position in Bristol Myers Squibb in the 3rd quarter worth $460,000. Assetmark Inc. increased its stake in Bristol Myers Squibb by 16.5% in the 3rd quarter. Assetmark Inc. now owns 240,622 shares of the biopharmaceutical company’s stock worth $10,852,000 after buying an additional 34,057 shares in the last quarter. Illinois Municipal Retirement Fund raised its holdings in Bristol Myers Squibb by 7.1% during the third quarter. Illinois Municipal Retirement Fund now owns 748,983 shares of the biopharmaceutical company’s stock valued at $33,779,000 after acquiring an additional 49,845 shares during the period. Finally, Haven Private LLC purchased a new position in shares of Bristol Myers Squibb in the third quarter valued at about $213,000. Institutional investors own 76.41% of the company’s stock.

Analysts Set New Price Targets

Several analysts recently issued reports on BMY shares. Leerink Partners lifted their target price on Bristol Myers Squibb from $54.00 to $60.00 and gave the company an “outperform” rating in a research note on Tuesday, January 13th. Bank of America upgraded shares of Bristol Myers Squibb from a “neutral” rating to a “buy” rating and lifted their price objective for the company from $52.00 to $61.00 in a research report on Monday, December 15th. Citigroup upped their target price on shares of Bristol Myers Squibb from $60.00 to $64.00 and gave the stock a “neutral” rating in a research report on Friday, February 6th. HSBC reiterated a “hold” rating and issued a $53.00 target price on shares of Bristol Myers Squibb in a research report on Wednesday, December 10th. Finally, Guggenheim restated a “buy” rating and set a $72.00 price target (up previously from $62.00) on shares of Bristol Myers Squibb in a report on Friday, February 6th. Eight analysts have rated the stock with a Buy rating, eleven have assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Hold” and an average target price of $59.20.

Bristol Myers Squibb Stock Down 0.3%

Shares of BMY opened at $59.78 on Friday. The firm has a market capitalization of $121.69 billion, a P/E ratio of 17.33, a P/E/G ratio of 0.17 and a beta of 0.29. Bristol Myers Squibb Company has a 12-month low of $42.52 and a 12-month high of $63.33. The firm has a fifty day moving average price of $55.16 and a 200-day moving average price of $49.35. The company has a current ratio of 1.27, a quick ratio of 1.17 and a debt-to-equity ratio of 2.39.

Bristol Myers Squibb (NYSE:BMY) last posted its quarterly earnings results on Thursday, February 5th. The biopharmaceutical company reported $1.26 earnings per share for the quarter, missing the consensus estimate of $1.65 by ($0.39). The company had revenue of $12.50 billion for the quarter, compared to the consensus estimate of $12.24 billion. Bristol Myers Squibb had a net margin of 14.64% and a return on equity of 70.30%. The business’s revenue was up 1.3% on a year-over-year basis. During the same period in the prior year, the firm posted $1.67 EPS. Bristol Myers Squibb has set its FY 2026 guidance at 6.050-6.350 EPS. Equities research analysts expect that Bristol Myers Squibb Company will post 6.74 earnings per share for the current year.

Bristol Myers Squibb Increases Dividend

The company also recently declared a quarterly dividend, which was paid on Monday, February 2nd. Stockholders of record on Friday, January 2nd were paid a dividend of $0.63 per share. This is an increase from Bristol Myers Squibb’s previous quarterly dividend of $0.62. This represents a $2.52 annualized dividend and a dividend yield of 4.2%. The ex-dividend date was Friday, January 2nd. Bristol Myers Squibb’s payout ratio is 73.04%.

Bristol Myers Squibb Company Profile

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.